View more on these topics

Pharmaceuticals are the future for iShares

Pharmaceuticals are the right medicine for iShares as it brings in the iBloomberg European pharmaceuticals fund.

European pharmaceuticals is an exchange traded fund aimed at experienced investors looking for growth.

The fund will track the Bloomberg European pharmaceutical index. This consists of 29 companies which include Glaxosmithkline, Merck, Roche Holdings, Astrazeneca and Novartis.

This is the seventh exchange traded fund that iShares has introduced into the UK over the past year. The range includes funds that track the FTSE 100, FTSE TMT and FTSE ExUK indices, and funds that track the more specialist Bloomberg technology, financial and telecom indices. The company also has 58 funds in the US.

One of the biggest advantages that exchange traded funds have over unit trusts and investment trusts is their charges, which are much lower. Most unit trusts and investment trusts have an initial charge of anything up to five per cent and an annual charge of an average of between one and 1.5 per cent. However the iShares European pharmaceutical fund only has an annual charge of 0.5 per cent.

Although many markets have been hit by recent volatility, pharmaceuticals tend to be driven more by developments such as new drugs and treatments than market movements. Many pharmaceutical companies are currently benefiting from recent developments like the decoding of the human genome.

The Bloomberg European pharmaceuticals index reached 595.5 points on April 23, 2001, up from a 52-week low of 505 points on March 21, 2001.


Royal & SunAlliance – UK Prime Fund

Friday, 27 April 2001.Type: Open ended investment company.Aim: Income and growth by investing in around 30 UK stocks.Minimum investment: Lump sum £1,000, monthly £50.Investment split: Information technology 12.5 per cent, basic industries 12.7 per cent, financials 16.5 per cent, cyclical services 18.1 per cent, general industries 5.5 per cent, non-cyclical services 6.5 per cent, utilities […]

A consumer&#39s View

The Government would do well to keep a low profile on promoting stakeholder pension if it does not want to find itself accused of pushing people into loss-making investments.If, as seems likely, employees find when they receive their annual stakeholder statement this time next year that they have lost money, the vast majority will abandon […]

Nationwide throws out conversion resolution

Nationwide Building Society has thrown out a conversion resolution attempting to trigger windfalls for members on the grounds it is “legally invalid”.The decision rules out a demutualisation vote at the society&#39s AGM in July. The resolution, issued by carpetbagger Andrew Muir, challenged Nationwide&#39s windfall foundation which insists on new members signing away any demutualisation payouts […]

Revenue concedes there is no deadline for unbundling Peps

The Inland Revenue has admitted that fund managers are under no obligation to unbundle Pep transfers by an October 6 dead- line it had previously set.The Revenue says it will now issue a clarification of its March bulletin which said that Pep managers will be obliged to offer partial transfers by October 6 this year. […]


News and expert analysis straight to your inbox

Sign up


    Leave a comment


    Why register with Money Marketing ?

    Providing trusted insight for professional advisers. Since 1985 Money Marketing has helped promote and analyse the financial adviser community in the UK and continues to be the trusted industry brand for independent insight and advice.

    News & analysis delivered directly to your inbox
    Register today to receive our range of news alerts including daily and weekly briefings

    Money Marketing Events
    Be the first to hear about our industry leading conferences, awards, roundtables and more.

    Research and insight
    Take part in and see the results of Money Marketing's flagship investigations into industry trends.

    Have your say
    Only registered users can post comments. As the voice of the adviser community, our content generates robust debate. Sign up today and make your voice heard.

    Register now

    Having problems?

    Contact us on +44 (0)20 7292 3712

    Lines are open Monday to Friday 9:00am -5.00pm